Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
8-K
Other Events
23 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 24
8-K
Travere Therapeutics Provides Corporate Update and 2024 Outlook
8 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
4 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Travere Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Other Events
21 Sep 23
8-K/A
Financial Statements and Exhibits
7 Sep 23
8-K
Completion of Acquisition or Disposition of Assets
5 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
S-8
Registration of securities for employees
3 Aug 23
8-K
Travere Therapeutics Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Entry into a Material Definitive Agreement
17 Jul 23
8-K
Other Events
31 May 23
8-K
Departure of Directors or Certain Officers
22 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Travere Therapeutics Reports First Quarter 2023 Financial Results
4 May 23
8-K
Other Events
1 May 23
DEF 14A
Definitive proxy
13 Apr 23
8-K
Changes in Registrant's Certifying Accountant
12 Apr 23
8-K
Travere Therapeutics Announces Proposed Public Offering of Common Stock
1 Mar 23
424B5
Prospectus supplement for primary offering
1 Mar 23
FWP
Free writing prospectus
28 Feb 23
424B5
Prospectus supplement for primary offering
27 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
8-K
Other Events
17 Feb 23
8-K
Travere Therapeutics Provides Corporate Update and 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 Oct 22
8-K
Other Events
13 Oct 22
8-K
Other Events
22 Aug 22
S-8
Registration of securities for employees
18 Aug 22
8-K/A
Departure of Directors or Certain Officers
17 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Travere Therapeutics Reports Second Quarter 2022 Financial Results
4 Aug 22
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
MACQUARIE GROUP LTD
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Eric M Dube
2 Feb 24
4
WILLIAM E. ROTE
2 Feb 24
4
Sandra Calvin
2 Feb 24
4
ELIZABETH E REED
2 Feb 24
4
Peter Heerma
2 Feb 24
4
Jula Inrig
2 Feb 24
4
Christopher R. Cline
2 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
4
ELIZABETH E REED
25 Jan 24
4
Eric M Dube
25 Jan 24
4
Christopher R. Cline
25 Jan 24
4
WILLIAM E. ROTE
25 Jan 24
4
Sandra Calvin
25 Jan 24
4
Peter Heerma
25 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
4
Jula Inrig
5 Jan 24
SC 13G/A
BlackRock Inc.
6 Oct 23
4
Peter Heerma
4 Oct 23
4
Christopher R. Cline
5 Sep 23
4
WILLIAM E. ROTE
5 Sep 23
4
ELIZABETH E REED
5 Sep 23
4
Eric M Dube
5 Sep 23
144
Notice of proposed sale of securities
5 Sep 23